Merck & Co is to buy the privately-held biotech Peloton for up to $2.2 billion, adding further oncology drugs to its pipeline as it searches for successors to cancer blockbuster Keytrud
AZ and Daiichi Sankyo announced positive top-line results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan, an antibody-drug conjugate, in patients with an advanced
Daiichi Sankyo had a day of mixed fortunes after advisers to the US regulator voted against approval for its leukaemia drug quizartinib, but recommended pexidartinib for a rare tumour.
Eli Lilly’s Cyramza has a new string to its bow after the FDA approved it as a second-line treatment for certain liver cancer patients, and received a further boost as the FDA removed a box
Having a continuous pulse on brand health is essential for pharmaceutical companies to inform strategic decisions and establish Key Performance Indicators (KPIs) in an ever-changing market